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Abstract 
Background 
Our approach to advancing the treatment of psychosis is to focus on key single symptoms and 
develop interventions that target the mechanisms that maintain them. In our theoretical 
research we have found worry to be an important factor in the development and maintenance 
of persecutory delusions. Worry brings implausible ideas to mind, keeps them there, and 
makes the experience distressing. Therefore the aim of the trial is to test the clinical efficacy 
of a cognitive-behavioral intervention for worry for patients with persecutory delusions and 
determine how the worry treatment might reduce delusions. 
Methods/Design 
An explanatory randomized controlled trial - called the Worry Intervention Trial (WIT) - 
with 150 patients with persecutory delusions will be carried out. Patients will be randomized 
to the worry intervention in addition to standard care or to standard care. Randomization will 
be carried out independently, assessments carried out single-blind, and therapy competence 
and adherence monitored. The study population will be individuals with persecutory 
delusions and worry in the context of a schizophrenia spectrum diagnosis. They will not have 
responded adequately to previous treatment. The intervention is a six-session cognitive-
behavioral treatment provided over eight weeks. The control condition will be treatment as 
usual, which is typically antipsychotic medication and regular appointments. The principal 
hypotheses are that a worry intervention will reduce levels of worry and that it will also 
reduce the persecutory delusions. Assessments will be carried out at 0 weeks (baseline), 8 
weeks (post treatment) and 24 weeks (follow-up). The statistical analysis strategy will follow 
the intention-to-treat principle and involve the use of linear mixed models to evaluate and 
estimate the relevant between- and within-subjects effects (allowing for the possibility of 
missing data). Both traditional regression and newer instrumental variables analyses will 
examine mediation. The trial is funded by the UK Medical Research Council (MRC)/NHS 
National Institute of Health Research (NIHR) Efficacy and Mechanism Evaluation (EME) 
Programme. 
Discussion 
This will be the first large randomized controlled trial specifically focused upon persecutory 
delusions. The project will produce a brief, easily administered intervention that can be 
readily used in mental health services. 
Trial registration 
Current Controlled Trials ISRCTN23197625 
Keywords 
Delusions, Persecutory, Worry, CBT, Schizophrenia 
Background 
Schizophrenia, the core psychotic illness, falls into the top ten medical disorders causing 
disability worldwide. It contains a heterogeneous collection of symptoms that cluster into 
many separate factors (for example, [1]). Studying single symptoms has emerged as a way of 
making progress with the complex problem of schizophrenia spectrum diagnoses. One of the 
key symptoms is persecutory delusion. This is the unfounded belief that others are 
deliberately trying to harm the person [2]. In psychosis, persecutory delusions are very 
frequent (for example, [3]), particularly distressing for patients (for example, [4]), are often 
acted upon (for example, [5]), and are a predictor of admission to psychiatric hospital (for 
example, [6]). Paranoid thinking is associated with increased rates of suicide attempts (for 
example, [7]) and cause particular problems for carers (for example, [8]). Persecutory 
delusions are a key clinical symptom for which improvements in treatment are greatly 
needed. Many patients do not respond to neuroleptic medication, relapse is common, and 
adherence to these treatments is problematic [9]; furthermore, the first generation of generic 
cognitive behavioral (CBT) approaches only show weak to moderate effects (for example, 
[10]) and have not been shown to change key causal factors [11]. In the last ten years there 
have been considerable advances in understanding persecutory delusions but these have not 
yet been translated into treatment. 
Theoretical rationale 
We have developed a theoretical model of the development of persecutory delusions [12,13]. 
Delusions arise from a number of interacting factors, but worry and associated processing are 
given a central role in the model. The connection is plausible - worry brings unlikely and 
distressing ideas to mind and keeps them there - and has been established empirically. It has 
been shown that worry is extremely common in individuals with persecutory delusions, that it 
is especially associated with more distressing persecutory delusions, and that it is a predictor 
of symptom persistence (for example, [14-18]). Other studies have also shown that worry is 
associated with non-clinical paranoia and predicts its occurrence [19-21]. Furthermore, in a 
new longitudinal study of over two thousand people taking part in the British Psychiatric 
Morbidity Survey, worry was shown to predict the new occurrence of paranoid thinking over 
an 18-month period [22]. Drawing upon the theoretical literature for generalized anxiety 
disorder, we have shown that worry in individuals with persecutory ideation is associated 
with catastrophizing (characterized as the worrier posing internal, automatic questions of the 
form „what if this bad thing happens?‟) and positive and negative meta-cognitive beliefs 
[14,16,19]. 
The pilot study 
On the basis of this work we have completed a pilot study examining the impact of a brief 
cognitive-behavioral worry intervention for patients with persecutory delusions [23]. The aim 
was to treat the clinical problem of worry in patients with delusions but also to examine the 
subsequent impact on persecutory delusions. This is known as an interventionist-causal 
model approach; „it [the interventionist-causal approach] connects causation with the 
practical interests of psychiatry, defining causation in terms of “what would happen under 
interventions”, a question of key interest to those of us whose interest is ultimately in 
intervening to prevent and treat illness‟ [24]. Twenty-four patients with persistent persecutory 
delusions were recruited. Half were randomized to the intervention in addition to their 
standard psychiatric care and half were randomized to the control group (standard psychiatric 
care). Assessments were carried out at baseline, end of treatment (one month), and at follow-
up (two months). There was a large effect size reduction in worry (Penn State Worry 
Questionnaire [25]) and also in the persecutory delusions (Psychotic Symptoms Rating Scale 
[26]). One in three patients showed a 25% or greater reduction in worry and the delusion. 
Changes in worry were associated with changes in persecutory delusions. However the trial 
assessments were not carried out blind and the sample size was small. A more rigorous 
evaluation is now required. 
Research objectives and hypotheses approve 
The project has two main objectives: 
1. Clinical outcome: To test the clinical efficacy of a brief cognitive-behavioral intervention 
for worry for patients with persecutory delusions. 
2. Explanatory mechanisms: To determine how the worry treatment reduces persecutory 
delusions. 
The trial hypotheses are: 
1. A worry intervention will reduce levels of worry in individuals with persecutory 
delusions. 
2. A worry intervention will reduce persecutory delusions, especially levels of distress. 
3. The improvements will be maintained at follow-up. 
4. The treatment-specific mediator for changes in persecutory delusions will be worry and 
associated mechanisms (catastrophizing, meta-cognitive beliefs including stop rules, and 
intolerance of uncertainty). 
Methods/Design 
The trial is a randomized controlled evaluation. Patients with persecutory delusions will be 
randomized to the worry intervention in addition to standard psychiatric care or to standard 
psychiatric care (see Figure 1). A psychological intervention control group is not included in 
the design. We will instead examine how the treatment works by including repeated measures 
of worry and associated processes. Non-specific therapist factors will also be assessed [27]. 
Randomization will be carried out independently, via an on-line system, by the Oxford 
Cognitive Health & Neuroscience Clinical Trials Unit. Stratification will be by center. 
Assessments will be carried out by raters blind to allocation. The success of the blinding will 
be monitored and where there are breaks of blind another assessor will be used. The 
reliability of the raters on the key interviewer measures will be formally assessed. Embedded 
within the design will be measures that elucidate how the treatment works. The trial has 
received a favorable opinion from the NHS Research Ethics Service Oxfordshire REC B 
(reference: 11/SC/0001). Written informed consent is received from all patients entering the 
trial. We will follow the MRC Guidelines for Good Clinical Practice in Clinical Trials (1998) 
[28] in the running of the trial. The Consolidated Standards of Reporting Trials (CONSORT) 
2010 Statement, and the extension for non-pharmacologic treatment [29], will be followed for 
reporting the trial. 
Figure 1 Flow diagram for the Worry Intervention Trial 
Participants 
Patients will be recruited from two mental health National Health Service (NHS) Trusts: 
Oxford Health NHS Foundation Trust and Southern Health NHS Foundation Trust. Full 
details of the patient recruitment process are being recorded. The inclusion criteria are as 
follows: 1) a current persecutory delusion as defined by Freeman and Garety [2]; 2) scoring 
at least three on the conviction scale of the PSYRATS [26]; 3) that the delusion has persisted 
for at least three months; 4) a clinical diagnosis of schizophrenia, schizoaffective disorder or 
delusional disorder (that is, diagnosis of non-affective psychosis (F2) in the International 
Classification of Diseases and Diagnostic and Statistical Manual IV); 5) a clinically 
significant level of worry, as indicated by scores above 44 on the Penn State Worry 
Questionnaire (see [30]); 6) aged between 18 and 65; and 7) where major changes in 
medication are being made, entry to the study would not occur until at least a month after 
stabilization of dosage. It should be noted that we will be seeing patients when the main 
treatment for delusions, neuroleptic medication, has generally been tried at length and their 
delusions are relatively stable (persistent). Criteria for exclusion are as follows: 1) a primary 
diagnosis of alcohol dependency, substance dependency, or personality disorder; 2) organic 
syndrome or learning disability; 3) a command of spoken English inadequate for engaging in 
therapy; or 4) currently having individual cognitive behavioral therapy (though previous CBT 
experience is not an exclusion). 
Planned interventions 
The worry intervention will be provided in six sessions over eight weeks by two clinical 
psychologists. This is an increase in the number of sessions used in the pilot, since the 
patients requested extra sessions. The eight-week window will allow some flexibility for 
appointment times and the extension of intervals between the final two sessions. The 
intervention is designed to provide clear and simple messages for patients to take into their 
day-to-day lives. A series of session booklets have been produced. The worry reduction 
strategies included are indicated in the anxiety literature to be effective at reducing worry and 
do not challenge or review the delusion itself. Key influences from the generalized anxiety 
disorders literature were Butler et al. [31], Dugas and Ladouceur [32], Wells [33] and Leahy 
[34]. The main techniques are psychoeducation about worry, reviewing of positive and 
negative beliefs about worry, increasing awareness of the initiation of worry and 
identification of individual triggers, learning to „let go‟ of worry, use of worry periods, 
substituting problem-solving in place of worry, and relaxation exercises. Homework 
exercises are set between sessions. Sessions will be taped for assessment of adherence and for 
competence [35]. Patients will also be asked to complete an assessment of the therapist‟s 
empathy [36]. Standard care is delivered according to national and local service protocols and 
guidelines. During hospitalization standard care usually involves prescription of anti-
psychotic medication, and to some extent occupational therapy activities and exercise groups. 
Following discharge, the level of standard care varies according to the needs of the 
individual. However, this usually consists of prescription of anti-psychotic medication, visits 
from a community mental health worker and regular outpatient appointments with a 
psychiatrist. Service use will be measured using the Client Service Receipt Inventory (CSRI) 
[37]. The CSRI covers services provided by the National Health Service, other health and 
social care agencies, the criminal justice system and informal carers. Antipsychotic 
medication data will be extracted from medical records and dosages converted into 
chlorpromazine equivalents. 
Measures 
The key outcome measures will be levels of worry as assessed by the Penn State Worry 
Questionnaire (PSWQ) [25] and levels of persecutory delusions as assessed by the Psychotic 
Symptoms Rating Scale - Delusions (PSYRATS) [36]. These are the best available measures 
of worry and delusions, with established psychometric properties. Secondary outcome 
measures will be a well-being measure (Warwick-Edinburgh Mental Well-being Scale, 
WEMWBS) [38], the Paranoid Thoughts Scale (GPTS) [39], the Perseverative Thinking 
Questionnaire [40], an adapted service user-led outcome measure [41], and the Positive and 
Negative Symptom Scale [42]. We will also record service use (including medication 
consumption), adverse events, and hospital admission data using the (Client Service Receipt 
Inventory; CSRI) [37]. For examination of mediation we will include: the Beck Anxiety 
Inventory [43], the catastrophizing interview [44,45], the Meta-Cognitions Questionnaire 
[46], the stop rule checklist [47] and the Intolerance of Uncertainty Questionnaire [48]. 
At baseline, in order to examine additional moderators of outcome, we will also ask 
participants to complete assessments of intellectual functioning (Wechsler Adult Intelligence 
Scale, WAIS) [49], illicit drug use (Maudsley Addiction Profile, MAP) [50], illness and 
treatment representations [51], probabilistic reasoning [52], and working memory [53]. 
Assessment and follow-up 
The outcome measures will be completed before therapy (0 weeks), at the end of therapy (8 
weeks) and at a follow-up (24 weeks). These can be completed in a single session with a 
research assessor. The majority of assessments are self-report measures; the interviewer rated 
PSYRATS and PANSS will be taped for reliability purposes. All the data entry for the two 
main outcomes will be double checked. The baseline assessment must be completed before 
randomization. The end of therapy assessment must be carried out after therapy has been 
completed. We will endeavor to have the repeat assessments carried out at exactly the timings 
specified, but will allow a two-week window for the post therapy assessment and a one-
month window for the follow-up assessment. Participants will be paid £15 for each 
assessment session, and travel expenses will also be paid. 
Assessment of safety 
The following events in trial patients are considered as adverse events: 1. All deaths. 2. 
Suicide attempts. 3. Serious violent incidents. 4. Admissions to secure units. 5. Formal 
complaints about therapy. We will also scrutinize any instances of patients being admitted to 
psychiatric hospital in the period of the therapy. These adverse events are likely to come to 
the attention of the assessor or therapist but we will also check medical notes at the end of a 
participant‟s time in the trial. 
Sample size 
Recruitment will be split equally across centers. In a conservative fashion we power the study 
to detect moderate effect sizes. In the pilot study the effect sizes were large: worry (PSWQ 
mean difference = 10.00 SD = 9.50) = 1.05; persecutory delusion (PSYRATS Mean 
difference = 2.91 SD = 2.15) = 1.35. A simple two-tailed t-test with 60 people per group 
would provide 90% power to detect an effect size of 0.60 at a significance level of .05. It 
would have 80% power to detect an effect size of 0.52. In practice, further power will be 
gained by use of multiple regression. Drop-out from the assessments in the pilot was low - 
13%. The intervention is brief and the time in the trial will be relatively brief (6 months). 
Therefore conservatively allowing for 20% drop-out, 150 people will need to be recruited to 
enable full data to be obtained from 120 participants (60 in each condition). 
Statistical analysis 
All main analyses will be carried out at the end of the last follow-up assessments (that is, 
there will be no interim analyses) and will be based on the intention-to-treat principle, with 
due consideration being given to potential biases arising from loss to follow-up. Random 
effects regression models will be fitted to the repeated measures to estimate treatment effects 
for outcomes, controlling for treatment center, in-patient status and the corresponding 
baseline assessment for the outcome under investigation. We will allow for the presence of 
missing outcome data under the assumption that the data are Missing At Random (MAR), 
using the terminology of Little and Rubin [54], with the possible addition of inverse 
probability weighting to adjust for the possible role of non-adherence to allocated treatment 
and other intermediate outcomes as predictors of future loss to follow-up [55]. Stata will be 
used for these main analyses. Secondary analyses to investigate putative meditational 
mechanisms, but also the effect of receipt of an adequate dose of treatment (CACE 
estimation), will be carried out; these will use methods similar to those of Baron and Kenny 
[56] but also the newer approach of instrumental variables analysis to allow for the omitted 
variables problem that is, hidden confounding [55-58]. MPlus and Stata will be used for these 
analyses. 
Research governance 
Oxford University is the research sponsor. NHS ethical and R&D approvals have been 
obtained before trial commencement. For trial management we follow the MRC Guidelines 
on Good Clinical Practice in Clinical Trials [28]. A Trial Steering Committee (TSC) has been 
formed, which includes an independent chair and two other independent members, including 
a service user. A Data Monitoring and Ethics Committee (DMEC) has been formed, which 
has a clinician as independent chair and a further clinician and statistician. 
Discussion 
The first generation of cognitive-behavioral therapies for psychosis now lags behind the 
transformation in recent years in understanding the causes of psychotic experiences. We have 
recently discussed how treatments for delusions can be improved [59] by focusing on one 
putative causal factor at a time, by showing that an intervention can change it, and by 
examining the subsequent effects on the delusional beliefs. There have now been a number of 
small pilot studies taking this approach [60,61], but the WIT study will be the first full-scale 
clinical evaluation. A key clinical advantage for the worry intervention is that rates of 
engagement seem to be higher because it works on a problem that has been agreed upon with 
the patient and it does not directly dispute the validity of the delusional beliefs. Furthermore 
it is a brief, structured intervention, which, if shown to work, could readily be disseminated 
into mental health services. However it is not suitable for patients with persecutory delusions 
who do not report worry; this appears, from the empirical literature and our initial recruitment 
into the trial, to be a small group but full information on this will be gathered for reporting 
with the trial results. The trial is funded for 30 months and began in October 2011. Final 
outcome assessments will be complete by the end of November 2013. Therefore the outcome 
results will become available in 2014. 
Trial status 
The trial began patient recruitment in November 2011. Recruitment remains open until July 
2013. 
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